Virtual Library
Start Your Search
Heidi A.I. Grosjean
Author of
-
+
P09 - Health Services Research/Health Economics - Real World Outcomes (ID 121)
- Event: WCLC 2020
- Type: Posters
- Track: Health Services Research/Health Economics
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P09.08 - Age-Related Outcomes of First-Line Pembrolizumab in a Real-World Non-Small-Cell Lung Cancer (NSCLC) Cohort (ID 3451)
00:00 - 00:00 | Presenting Author(s): Heidi A.I. Grosjean
- Abstract
Introduction
On the basis of the KEYNOTE-024 trial, pembrolizumab became standard of care in Canada for patients with PD-L1 positive (≥50%) NSCLC. However, robust real-world data assessing outcomes in this treatment setting, especially amongst patients of different age groups, are lacking. The primary objective of this study was to examine age-related outcomes in a real-world cohort of NSCLC patients treated with pembrolizumab.
Methods
Patients who initiated first-line, single-agent pembrolizumab for treatment of PD-L1-positive (≥50%) NSCLC in Alberta, Canada from 3/1/2017 to 12/30/2019 were included. Data cutoff date was 05/01/2020. Patient demographics and clinical outcomes were collected retrospectively. The primary outcome was median overall survival (mOS) among age-stratified groups. Secondary outcomes were median time-to-treatment failure (mTTF) and objective response rate (ORR). Kaplan-Meier survival curves were used to determine survival outcomes, and compared with the log-rank test. A Cox-proportional hazard model was constructed with relevant clinical characteristics to assess their impact on survival.
Results
Of the 327 patients included in the analysis, 31% (n=101) were <65 years old, 45% (n=147) were between 65-74 years old and 24% (n=79) were ≥75 years old. mOS (95% CI) was 12.3 mo (8.3-17.5) for the entire cohort. Stratified by age, mOS between the groups were not significantly different (15.4 mo [6.0-23.8], 9.3 mo [6.8-16.5], and 14.4 mo [8.2-23.2] for the <65, 65-74, and ≥75 age groups, respectively; p=0.81). In addition, neither the mTTF nor ORR differed between age groups (p=0.59 and p=0.86, respectively). All three groups had similar 90-day mortality rates after treatment initiation; 29.7%, 23.8%, and 17.7% (p=0.18) and similar survival at 12 months (39.6%, 32.7%, and 31.6%, p=0.43).
In a multivariate model accounting for sex, age, tumor histology, baseline autoimmune disease, presence of brain metastases, and Eastern Cooperative Oncology Group Performance Status (ECOG-PS), only ECOG-PS ≥ 2 was an independent prognosticator of poor survival (HR 2.9; 95% CI 2.1-4.0, P < 0.0001).
Table 1. Clinical outcomes as stratified by age <65 Cohort (n=101)
65-74 Cohort (n=147)
≥75 Cohort (n=79)
p-value mOS (95% CI)
15.4 (6.0-23.8)
9.3 (6.8-16.5)
14.4 (8.2-23.2)
0.81a mTTF (95% CI)
4.5 (2.1-5.5)
3.7 (2.8-4.9)
5.6 (2.8-7.7)
0.59a %ORR^ 29.6% 32.5% 33.9% 0.86b % alive at 90 d 70.3% 76.2% 82.3% 0.18b % alive at 12 mo 39.6% 32.7% 31.6% 0.43b ^Calculated from evaluable responses. alog-rank test. bchi-squared test.
Conclusion
There were no significant differences in mOS, mTTF, or ORR between the age-stratified treatment groups in our sample. Notably, we observed a ~25% mortality rate within the first 90-days of treatment initiation, and a mOS of only 12.3 mo. ECOG-PS ≥ 2 was the only significant prognosticator of poor OS. Although we conclude that age alone should not be a contraindication to treatment with first-line pembrolizumab in PD-L1-positive NSCLC, survival outcomes are modest compared to the KEYNOTE-024 trial, with poor ECOG-PS being the strongest negative prognostic factor.